Hanall Biopharma Co., Ltd.

Immunomet Therapeutics Inc.

Korea Research Institute of Bioscience and Biotechnology

Jae Kap Jeong

Sung Wuk Kim

Eun Sun Kim

Seung Kook Park

Yeon Jung Song

Hyea Kyung Ahn

Dongok Shin

Hae-Young Yong

Min Sun Kim

Ji Sun Lee

Ha Na Kim

Sung Soo Jun

Hye Jin Heo

Hong Bum Lee

Hong Woo Kim

Song Young Kim

Tae Hyoung Yoo

Ji Ae Kook

Ji Hyun Park

Young Woo Lee

Hyun Ah Kang

Doo-Byoung Oh

Seonghun Kim

Ohsuk Kwon

Hung Keun Lee

Seo-il Kim

Jeong Haing Heo

The present disclosure relates to an isolated anti-FcRn antibody, which is an antibody binding to FcRn (stands for neonatal Fc receptor, also called FcRP, FcRB or Brambell receptor) that is a receptor with a high affinity for IgG or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune diseases using the antibody. The FcRn-specific antibody according to the present disclosure binds to FcRn non-competitively with IgG to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.

Antibody binding to FCRN for treating autoimmune diseases

The present invention relates to a guanidine compound and a use thereof, and more specifically, to a guanidine derivative showing excellent effects of inhibiting cancer cell proliferation, cancer metastasis, and cancer recurrence; a preparation method thereof; and a pharmaceutical composition containing the same as an active ingredient. Compared to existing drugs, the guanidine derivative according to the present invention shows excellent effects of inhibiting cancer cell proliferation, cancer metastasis, and cancer recurrence even with small doses, and may thus be effectively used in preventing or treating various cancers such as uterine cancer, breast cancer, stomach cancer, brain cancer, rectal cancer, colorectal cancer, lung cancer, skin cancer, blood cancer, liver cancer, etc., inhibiting cancer cell proliferation and cancer metastasis.

Biguanide compound and use thereof

Antibody binding to FcRn for treating autoimmune diseases

The present invention relates to a human antibody specific for FcRn that is a receptor with a high affinity for IgG, a production method thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune disease using the same. The FcRn-specific antibody according to the present invention can bind to FcRn non-competitively with IgG or the like to reduce serum auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.

FcRn-specific human antibody and composition for treatment of autoimmune diseases

The present invention relates to biguanide compounds and use thereof, more particularly, to biguanide derivatives exhibiting excellent effects for inhibition of cancer cell proliferation and inhibition of cancer metastasis and recurrence, a method for preparing the same, a pharmaceutical composition containing the same as an active ingredient, and a method of prevention or treatment of cancer comprising the step of administering an effective amount of the composition to a subject in need thereof.

Biguanide compounds and use thereof

The present invention relates to new uses of modified human tumor necrosis factor receptor-1 (TNFRI) polypeptide, and more particularly, to uses thereof for prevention and treatment of dry eye syndrome. The modified TNFRI or modified TNFRI fragment of the present invention has excellent TNF&#x3b1; neutralizing activity, and inhibits TNF&#x3b1; activity on the ocular surface of the patient to suppress inflammation induction effects related to dry eye. Therefore, the modified TNFRI or modified TNFRI fragment of the present invention exhibits remarkable effects in the prevention and treatment of dry eye syndrome, and thus can be very useful in the prevention and treatment of dry eye syndrome.

Uses of modified human tumor necrosis factor receptor-1 polypeptide

The present invention relates to a modified human tumor necrosis factor receptor-1 polypeptide to be coupled to a tumor necrosis factor in vivo or ex vivo, or to a fragment thereof. The modified human tumor necrosis factor receptor-1 polypeptide or the fragment thereof according to the present invention exhibit improved resistance against in vivo protease activity, and thus exhibit improved bioavailability and an improved absorption rate.

Modified human tumor necrosis factor receptor-1 polypeptide or fragment thereof, and method for preparing same

The present invention relates to a modified human tumor necrosis factor receptor-1 polypeptide which is capable of binding to a tumor necrosis factor in vivo or ex vivo, or to a fragment thereof. The modified human tumor necrosis factor receptor-1 polypeptide or the fragment thereof according to the present invention exhibit improved binding affinity to the tumor necrosis factor.

Modified human tumor necrosis factor receptor-I polypeptide or fragment thereof, and method for preparing same

Provided is a modified human tumor necrosis factor receptor-1 polypeptide or a fragment thereof that binds to a tumor necrosis factor in vivo or ex vivo. The modified human tumor necrosis factor receptor-1 polypeptide or fragment exhibits improved ability to bind tumor necrosis factor and resistance to proteases.

The present invention relates to beta-galactosidase derived from, a BgaC protein exhibiting the enzyme activity, and a method for using the same. The protein can be used in the modification and analysis of sugar chain and used as an anti-cancer agent.

[object Object]

Growing community of inventors

Suwon-si, South Korea

Jae Kap Jeong